Boehringer bets on oncolytic viruses in ViraTherapeutics deal

The German pharma paid $245 million to acquire the Austrian biotech, ​boosting a partnership the two companies inked in 2016.

By Ned Pagliarulo • Sept. 13, 2018

As EpiPen struggles, Walgreens, Kaleo ink Auvi-Q partnership

Auvi-Q will now be offered at Walgreens' roughly 9,800 locations at no cost for commercially insured patients eligible for Kaleo's patient support programs.

By Jacob Bell • Sept. 7, 2018

Health systems roll out generic manufacturing company to meet hospital needs

Catholic Health Initiatives, HCA and Mayo Clinic are just a few of the groups aiming to lower costs and increase access to generics through the newly-named Civica Rx.

By Jacob Bell • Sept. 6, 2018

Novartis slims down Sandoz, selling 2 units to Aurobindo for $1B

Roughly 300 products from Sandoz's oral solids and dermatology businesses will transfer to the Indian drugmaker.

By Andrew Dunn • Sept. 6, 2018

Mannkind stays afloat with United licensing deal

The struggling insulin drugmaker picks up $45 million through the deal, which should help stave off concerns about its ability to continue operations. 

By Ned Pagliarulo • Sept. 4, 2018

BioPharma Dive's 10 hottest stories of the summer

Readers were drawn to news from big pharmas, like Pfizer and Roche, as well as a landmark biotech approval and new drug launches. 

By Jacob Bell • Sept. 4, 2018

Emergent BioSolutions snaps up Narcan maker in $735M deal

Stepping into the opioid reversal market, Emergent will add an already-approved nasal naloxone to diversify its infectious disease-focused pipeline.

By Suzanne Elvidge • Aug. 29, 2018

Cigna, Express Scripts shareholders greenlight deal

About 90% of Cigna votes were cast in favor of the acquisition, yet the $67 billion deal is still subject to a number of regulatory approvals.

By Tony Abraham • Updated Aug. 27, 2018

Pfizer inks marketing deal for Exact's Cologuard

Exact said about 401,000 tests were performed during the first six months of 2018, leading to revenue of $193 million. The CEO now expects $700 million in sales for next year.

By Andrew Dunn • Aug. 22, 2018

Walmart, Anthem partner on Medicare program

Tie-ups between healthcare firms and retailers have ticked up, with Walmart now planning to offer discounts on OTC drugs for some Anthem customers.

By Daphne Howland • Aug. 20, 2018

Two Chinese biotechs sign $350M+ PD-L1 inhibitor deal

Kelun-Biotech and Harbour BioMed join the wave of companies vying to enter the checkpoint inhibitor market.

By Andrew Dunn • Aug. 20, 2018

In pursuit of new insulins, Novo may drop more than $800M on Ziylo

Pricing pressures and competition have pushed diabetes drugmakers to innovate. Novo's looking to do just that in buying the University of Bristol spinout and its glucose-binding molecules.

By Jacob Bell • Aug. 17, 2018

Pfizer puts up $425M in flu vaccines deal

A new research collaboration between the big pharma and Germany's BioNTech focuses on creating mRNA-based vaccines for preventing influenza.

By Jacob Bell • Aug. 16, 2018

With EngagedMedia, Aptus Health set to scale up patient adherence

As digital technologies rapidly transform the relationships between patients and pharmaceutical companies, Aptus Health adds a mobile-first, data-driven platform to its portfolio. 

Aug. 16, 2018

Catalent completes $130M acquisition of Juniper

The deal is the latest in the CDMO space aimed at beefing up services for pharmaceutical companies.

By Barbara Boughton • Aug. 15, 2018

Icahn raises white flag in Cigna-Express Scripts tiff

Activist investor Carl Icahn relinquished his fight to block Cigna's acquisition efforts after two high-profile advisory firms backed the deal.

By Tony Abraham • Aug. 14, 2018

Astellas acquires Quethera to expand ophthalmic pipeline

The buy is the Japanese pharma's latest bid to fuel growth through acquiring companies with experimental drugs.

By Barbara Boughton • Aug. 13, 2018

Perrigo to split off generic drugs unit

It's the latest indication of the pain felt by generic drugmakers as competition and pricing pressures hurt bottom lines.

By Barbara Boughton • Aug. 10, 2018

Emergent gets shot in the arm with $270M deal for PaxVax

Buying PaxVax will give Emergent two FDA-approved vaccines that the company expects to generate as much as $90 million in annual sales.

By Suzanne Elvidge • Aug. 10, 2018

Boehringer, Oxford BioMedica join on CF gene therapy project

Securing Oxford BioMedica's participation is indicative of the manufacturing hurdles present in gene therapy, particularly involving lentiviral vectors. 

By Suzanne Elvidge • Aug. 9, 2018

Sarepta further expands in gene therapy with $30M Lacerta deal

Though the biotech breezed through the second quarter on the back of Exondys 51, this new deal puts it in the competitive Pompe disease space.

By Andrew Dunn • Aug. 9, 2018

Allergan and Editas exercise CRISPR option

The big pharma will develop and commercialize EDIT-101 globally, while its smaller partner will co-develop and share profits and losses in the U.S.

By Suzanne Elvidge • Aug. 7, 2018

Icahn blasts Cigna-Express Scripts deal as among 'worst acquisitions in corporate history'

PBMs are under a political microscope too risky for Cigna shareholders, the activist investor warned, also citing threats from Amazon.

By David Lim • Aug. 7, 2018

Ironwood drops AstraZeneca deal, slashes jobs

Ending the agreement will lead to the loss of 125 jobs — primarily field-based sales employees — and termination costs of $10 million to $13 million.

By Suzanne Elvidge • Aug. 7, 2018

Allergan sells off dermatology drugs to Spain's Almirall

Almirall will pay $550 million in cash to bring the five drugs on board and anticipates the deal will be immediately accretive to earnings. 

By Andrew Dunn • Aug. 3, 2018